Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib neoadjuvant study in advanced thyroid cancer
ChiCTR2100048077Phase 2Completed
- Sponsor
- Tianjin People's Hospital
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in thyroid cancer, well-differentiated thyroid cancer (WDTC) and Medullary Thyroid Cancer (MTC), sponsored by Tianjin People's Hospital. Primary endpoints: Objective response rate, Actual operation rate and 1 more. Started May 2020; status: completed.
02
Drugs
anlotinib
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on ChiCTR2100048077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048077.